Cystic fibrosis (CF) is one of the most prevalent global congenital disorders, affecting some 70,000 individuals worldwide and 30,000 children and adults in the United States. While clinical efforts are expanding worldwide to improve diagnostic testing and treatment approaches for this progressive lung disease, targeted therapies for CF against any specific mutation remain elusive. The Cystic Fibrosis in Focus series gathers the latest information from leading medical experts devoted to advancing knowledge in pursuit of treating patients with CF. With education spanning topics such as pinpointing CF's underlying genetic basis, identifying specific mutations, improving clinical detection methods, and providing more targeted therapies, The Cystic Fibrosis in Focus series delivers the critical tools needed to improve care for CF patients.​ In Partnership with
Date | Title & Description | Contributors |
---|---|---|
2020-02-06 |
An In-Depth Look at the Evolution of Cystic Fibrosis Treatments Host: Paul Doghramji, MD Guest: Gregory Sawicki, MD, MPH Even though there currently isn’t a cure for cystic fibrosis, there may finally be hope on the horizon for the more than 70,000 people around the world who are living with this debilitatin... |
|
2020-02-06 |
An In-Depth Look at the Evolution of Cystic Fibrosis Treatments Host: Paul Doghramji, MD Guest: Gregory Sawicki, MD, MPH Even though there currently isn’t a cure for cystic fibrosis, there may finally be hope on the horizon for the more than 70,000 people around the world who are living with this debilitatin... |
|
2020-02-06 |
An In-Depth Look at the Evolution of Cystic Fibrosis Treatments Host: Paul Doghramji, MD Guest: Gregory Sawicki, MD, MPH Even though there currently isn’t a cure for cystic fibrosis, there may finally be hope on the horizon for the more than 70,000 people around the world who are living with this debilitatin... |
|
2016-12-12 |
Cystic Fibrosis: The Essential Role of Pancreatic Enzyme Replacement Therapy in Patient Care Host: John J. Russell, MD Guest: Suzanne Michel, MPH, RD, LDN Approximately 85-90% of patients with Cystic Fibrosis suffer from pancreatic insufficiency since birth, which significantly complicates the disease and adversely affects both quality of li... |
|
2016-11-22 |
Nontuberculous Mycobacteria (NTM) in Patients with Cystic Fibrosis Host: John J. Russell, MD Guest: Patrick Flume, MD Nontuberculous mycobacteria infection of the lung (a.k.a. NTM lung disease) is becoming increasingly common. In this activity, we are going to discuss how patients are evaluated and treated, as well ... |
|
2016-11-11 | Host: Barnett Mennen, MD Guest: Peter J. Mogayzel, Jr, MD, PhD, MBA This activity discusses the etiology of cystic fibrosis lung disease, the current clearance approaches and the role CFTR modulator therapy in the treatment of cystic fibrosis lung di... | |
2016-10-26 | Host: Barnett Mennen, MD Guest: Denis Hadjiliadis, MD, MHS, PhD Lung Transplantation is often considered for patients with cystic fibrosis. In this activity, we will discuss how patients are evaluated and listed, common complications, medications tha... | |
2016-10-25 | Host: Barnett Mennen, MD Guest: Erin McElroy Barker, LCSW Patients with cystic fibrosis and their families are at a higher risk for mental health issues which have been associated with other complications. In this activity, Ms. McElroy Barker will di... | |
2016-09-29 |
Rationale for Performing Airway Clearance for Patients with Cystic Fibrosis Host: Jennifer Caudle, DO Guest: Robert L. Zanni, MD, CPI Airway clearance is the primary therapy for patients with cystic fibrosis. In this activity, Dr. Zanni will discuss the rationale for performing airway clearance, as well as current mechanical... |
|
2016-08-01 | A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Flume PA, VanDevanter DR, Morgan EE, Dudle... |